Investigational (development stopped)Activin receptor IIB decoy proteinMuscle research
ACE-031
ACE-031 is a soluble activin receptor type IIB fusion protein that was tested in Duchenne muscular dystrophy; development stopped after safety signals.
What is ACE-031?
ACE-031 is a soluble activin receptor type IIB fusion protein that was tested in Duchenne muscular dystrophy; development stopped after safety signals. ACE-031 is an investigational compound: it has been studied in clinical trials but has no FDA approval, and its development was stopped.
Key takeaways
- ACE-031 is an investigational compound: it has been studied in clinical trials but has no FDA approval, and its development was stopped.
- PubMed indexes 12 papers on ACE-031 (2 tagged as clinical trials) as of October 19, 2026.
- ClinicalTrials.gov lists 4 registered studies using ACE-031.
- 5 vendors in our directory listed ACE-031 in their public catalog on October 19, 2026.
Regulatory & access status
ACE-031 is an investigational compound: it has been studied in clinical trials but has no FDA approval, and its development was stopped.
Sellers that market unapproved peptides for human use can receive FDA warning letters; our vendor directory links any letter we found on fda.gov.
How much research exists on ACE-031?
PubMed indexes 12 papers mentioning ACE-031 in the title or abstract, 5 of them from the last five years and 2 tagged as clinical trials (search run October 19, 2026; repeat the search).
Most relevant recent papers
- Gel Electrophoretic Detection of Black Market ACE-031. — Drug Test Anal, 2025
- ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus). — PLoS One, 2026
- ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus). — bioRxiv, 2025
- A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. — Muscle Nerve, 2013 · clinical trial
- Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. — Muscle Nerve, 2017 · clinical trial
- The relationship between myodural bridges, hyperplasia of the suboccipital musculature, and intracranial pressure. — PLoS One, 2022
Registered clinical studies
ClinicalTrials.gov lists 4 studies with ACE-031 as an intervention (see all). Most recent:
- Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy — NCT01099761 · Phase 2 · terminated · started 2010-04
- A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers — NCT00755638 · Phase 1 · completed · started 2008-09
- Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy — NCT01239758 · Phase 2 · terminated · started 2010-10
- A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women — NCT00952887 · Phase 1 · completed · started 2009-08
What the evidence does not show
- Paper counts measure research attention, not whether ACE-031 works or is safe.
- No FDA review of any "research use only" product's identity, purity, sterility or dose.
Research suppliers that list ACE-031
5 vendors in our directory listed a product matching ACE-031 in their public catalog on October 19, 2026. Listed alphabetically; a listing is not an endorsement. Research use only.
Prices per mg, where we could verify them, are on our price comparison.
ACE-031 reconstitution math
Lab arithmetic only, not dosing guidance: use the peptide calculator to turn a vial size and diluent volume into a concentration.
ACE-031 FAQ
Is ACE-031 FDA-approved?
ACE-031 is an investigational compound: it has been studied in clinical trials but has no FDA approval, and its development was stopped.
Is ACE-031 safe?
Safety data come from the published studies listed on this page; read them in full. Products sold as "research use only" have no FDA review of their purity, sterility or dose.
How much research is there on ACE-031?
PubMed indexes 12 papers on ACE-031 (2 tagged as clinical trials) as of October 19, 2026.
Who sells ACE-031?
Biotech Peptides, Core Peptides, NuScience Peptides, Peptide Worldwide, Swiss Chems listed it on their public catalogs when we checked; a listing is not an endorsement.
Related compounds
Follistatin-315FollistatinGHRHGHRP-6SomatropinHexarelinMGFTesamorelinAll growth hormone & ghrh